The business model of Harvard Bioscience Inc is focused on providing innovative tools and solutions to life science researchers. The company specializes in developing and manufacturing scientific instruments, systems, and lab supplies that are used in drug discovery, disease research, and other biomedical applications. These products cater to a wide range of research fields, including cell biology, neurobiology, stem cell research, and physiology. Harvard Bioscience Inc aims to support scientists and enhance their research capabilities by delivering high-quality products that enable efficient and accurate experimentation.

Harvard Bioscience Inc is primarily active in the life sciences industry.

The main competitors of Harvard Bioscience Inc in the market include companies such as Thermo Fisher Scientific, Bio-Rad Laboratories, and PerkinElmer Inc. These companies operate in the life sciences and biotechnology industries, offering a range of products and solutions that compete with Harvard Bioscience Inc's offerings. By providing innovative scientific instruments, tools, and services, these competitors create a competitive landscape within the market. Harvard Bioscience Inc continually faces the challenge of distinguishing its products and maintaining a competitive edge against these major players in the industry.

Harvard Bioscience Inc is a leading global developer, manufacturer, and marketer of specialized products and technologies that advance life science research. Established in 1901, the company has a rich history of innovation and has been at the forefront of scientific advancements. With a focus on providing cutting-edge tools and solutions, Harvard Bioscience Inc has become a trusted partner for researchers and scientists worldwide. Their dedication to delivering high-quality products and services has enabled them to establish a strong presence in the life science industry. Today, Harvard Bioscience Inc continues to drive innovation and shape the future of scientific discovery.

Harvard Bioscience Inc has achieved several significant milestones. The company successfully expanded its product portfolio and strengthened its global presence through strategic acquisitions. They developed innovative technologies and solutions, enhancing their position as a leading provider of scientific instruments. Harvard Bioscience Inc also established collaborations with renowned research institutions and industry partners, fostering scientific advancements and knowledge sharing. The company's relentless commitment to research and development enabled them to introduce groundbreaking products that revolutionized various scientific disciplines. Harvard Bioscience Inc's commitment to excellence and continuous innovation has propelled them to become a trusted name in the scientific community.

Harvard Bioscience Inc primarily operates in the United States, with headquarters in Holliston, Massachusetts. The company also has a presence in Canada, Europe, and Asia, serving customers globally. With a focus on providing advanced tools and solutions for life science research, Harvard Bioscience Inc has established itself as a leading provider of innovative products and services in the field.

Harvard Bioscience Inc represents a set of core values and a strong corporate philosophy. The company is committed to providing innovative solutions for life science research and advancing scientific discovery. Harvard Bioscience Inc prioritizes integrity, collaboration, and excellence in every aspect of its operations. With a focus on customer satisfaction, the company strives to deliver cutting-edge technologies and exceptional service to researchers worldwide. Through its dedication to promoting scientific advancement and improving the understanding of life sciences, Harvard Bioscience Inc has established itself as a trusted and reliable partner in the research community.

Analysts currently set an average price target of 2.04 USD for the Harvard Bioscience stock (median: 2.04 USD), implying -66.2 % versus the latest price. The consensus is based on 8 analyst ratings.

Harvard Bioscience Analyst Price Targets 2026

8 analysts currently rate the Harvard Bioscience stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Harvard Bioscience to generate revenue of 94.45 M USD and earnings per share of 1.00 USD.

Harvard Bioscience Analyst Price Targets 2026

Converted at the current exchange rate, the Harvard Bioscience share trades at 5.29 EUR (6.04 USD).

The Harvard Bioscience share (HBIO) is listed on 4 stock exchanges, including: NASDAQ (HBIO), Frankfurt (HBI.F), München (HBI.MU), Düsseldorf (HBI.DU).

Harvard Bioscience Inc is a globally operating company specializing in the sale of scientific instruments and devices for the life sciences. The company is divided into three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. In the Life Science Research segment, Harvard Bioscience offers a wide range of instruments for the study of cells, tissues, and organs. This includes devices for cell culture, DNA transfection, microinjection, and cell monitoring. Products for tissue research include cell slicers, tissue homogenizers and disruptors, as well as sample manipulation devices. Harvard Bioscience also offers organ perfusion systems, organ baths, and organ isolation devices for organ research. The Analytical Instruments segment focuses on instruments for the analysis of biological samples. This includes pH meters, conductivity meters, pipettes, density meters, and osmometers. The Bioscience Tools segment offers a broad portfolio of tools and consumables for the life sciences. This includes micro pipettes, microinjection needles, cell culture plates, and PCR tubes. A key concept of Harvard Bioscience is the high quality of its products. Most instruments and devices are developed and manufactured in their own production facilities. The company emphasizes strict quality testing and control, as well as compliance with international norms and standards. Harvard Bioscience sells its products worldwide through a network of distribution partners and direct sales channels. The majority of customers are research institutes, universities, biotechnology and pharmaceutical companies, as well as government organizations. The company works closely with its customers and partners to customize products to meet their needs and fulfill specific requirements. A key growth strategy of Harvard Bioscience is continuous innovation and development of its products. The company invests a significant portion of its revenue in research and development each year. By acquiring companies that develop innovative biotechnological technologies, the company aims to strengthen its strong position in the industry and expand its presence in the international market. Overall, the business model of Harvard Bioscience is focused on providing high-quality scientific instruments and technologies for the life sciences. The company's emphasis on research and development and collaboration with customers and partners distinguish it and ensure continuous growth and success. Answer: The Harvard Bioscience Inc is a global company specializing in selling scientific instruments and devices for the life sciences. They have three business segments: Life Science Research, Analytical Instruments, and Bioscience Tools. They offer a wide range of instruments for cell, tissue, and organ research. They also have instruments for analyzing biological samples and a portfolio of tools and consumables for the life sciences. They focus on high-quality products and comply with international standards. They sell their products worldwide through various channels and work closely with customers and partners. Continuous innovation and development are important to their growth strategy.

The expected revenue of Harvard Bioscience is 94.45 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Harvard Bioscience is 4.33 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Harvard Bioscience is currently 6.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Harvard Bioscience stock.

The price-to-sales ratio (P/S) of Harvard Bioscience is currently 0.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Harvard Bioscience stock.

The Eulerpool Quality Score for Harvard Bioscience is 1/10.

The ISIN of Harvard Bioscience is US4169061052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Harvard Bioscience is 578107. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Harvard Bioscience is HBIO. The ticker symbol is used to trade Harvard Bioscience shares on the stock exchange.

Harvard Bioscience paid dividends every year for the past 0 years.

Harvard Bioscience is assigned to the 'Health' sector.

The dividends of Harvard Bioscience are distributed in USD.